


Financial factsheet


Q3 2026

April 1, 2026 – June 30, 2026




SCHOTT Pharma

Revenue bridge
(in EUR m)



Revenue by region
(in EUR m)



Results of operations (in EUR m)	Q3 2026	Q3 2025	Δ in %
Revenue	281.8	256.2	+10.0%
Share of high-value solutions (HVS)	59%	60%	-
EBITDA	75.5	82.8	-8.8%
EBITDA margin	26.8%	32.3%	-
EBIT	53.3	63.1	-15.6%
EBIT margin	18.9%	24.6%	-
Financial result	-2.0	-3.1	-34.5%
Income tax expenses	-12.3	-14.4	-14.9%
Profit for the period	39.0	45.6	-14.5%
Earnings per share (in EUR)	0.26	0.30	-13.3%


Financial position (in EUR m)	Q3 2026	Q3 2025
Cash flows from operating activities	45.6	55.2
Cash flows from ongoing investing activities	-32.1	-37.9
Free cash flow	13.5	17.3

Net assets (in EUR m)	Jun. 30, 2026	Sep. 30, 2025
Working capital	245.4	199.3
Working capital in % of revenue	21.8%	20.2%
Equity ratio	58.9%	55.9%
Net debt	106.0	122.2

Employees	Jun. 30, 2026	Sep. 30, 2025
Headcount (as of the reporting date)	5,002	4,811

Drug Containment Solutions (DCS)


Revenue bridge
(in EUR m)



Results of operations (in EUR m)	Q3 2026	Q3 2025	Δ in %
Revenue	158.9	142.8	+11.3%
EBITDA	37.9	38.3	-1.1%
EBITDA margin	23.8%	26.8%	-
EBIT	27.7	29.2	-5.3%
EBIT margin	17.4%	20.5%	-

Drug Delivery Systems (DDS)

Revenue bridge
(in EUR m)




Results of operations (in EUR m)	Q3 2026	Q3 2025	Δ in %
Revenue	123.2	113.5	+8.6%
EBITDA	36.3	41.9	-13.4%
EBITDA margin	29.4%	36.9%	-
EBIT	24.5	31.5	-22.2%
EBIT margin	19.9%	27.7%	-

Financial factsheet

9M 2026

October 1, 2025 – June 30, 2026



SCHOTT Pharma

Revenue bridge
(in EUR m)



Revenue by region
(in EUR m)



Results of operations (in EUR m)	9M 2026	9M 2025	Δ in %
Revenue	769.8	739.2	+4.1%
Share of high-value solutions (HVS)	57%	57%	-
EBITDA	205.3	213.3	-3.8%
EBITDA margin	26.7%	28.9%	-
EBIT	139.7	156.0	-10.4%
EBIT margin	18.2%	21.1%	-
Financial result	-6.2	-9.6	-35.6%
Income tax expenses	-30.2	-32.7	-7.8%
Profit for the period	103.4	113.7	-9.0%
Earnings per share (in EUR)	0.68	0.75	-9.3%


Financial position (in EUR m)	9M 2026	9M 2025
Cash flows from operating activities	140.7	127.7
Cash flows from ongoing investing activities	-81.8	-88.2
Free cash flow	58.9	39.6

Net assets (in EUR m)	Jun. 30, 2026	Sep. 30, 2025
Working capital	245.4	199.3
Working capital in % of revenue	21.8%	20.2%
Equity ratio	58.9%	55.9%
Net debt	106.0	122.2

Employees	Jun. 30, 2026	Sep. 30, 2025
Headcount (as of the reporting date)	5,002	4,811

Drug Containment Solutions (DCS)


Revenue bridge
(in EUR m)



Results of operations (in EUR m)	9M 2026	9M 2025	Δ in %
Revenue	445.4	413.9	+7.6%
EBITDA	109.7	99.6	+10.1%
EBITDA margin	24.6%	24.1%	-
EBIT	80.0	72.1	+11.0%
EBIT margin	18.0%	17.4%	-

Drug Delivery Systems (DDS)

Revenue bridge
(in EUR m)



Results of operations (in EUR m)	9M 2026	9M 2025	Δ in %
Revenue	325.1	325.8	-0.2%
EBITDA	95.7	114.4	-16.3%
EBITDA margin	29.5%	35.1%	-
EBIT	60.5	85.2	-28.9%
EBIT margin	18.6%	26.1%	-